Navigation Links
InNexus Completes Previously Announced Private Placement
Date:1/27/2009

BRITISH COLUMBIA, Canada, Jan. 27 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), announced today that it has completed a second private placement on the same terms and conditions as the private placement that was completed 12 December 2008.

The private placement, totaled $2,207,000 of 10% unsecured convertible debentures. Each Debenture will be convertible into common shares of InNexus at the rate of one common share for each $0.10 of debt converted. The Debenture will have a term of 2 years. In the course of this private placement, InNexus has redeemed $624,000 in value of preferred shares which was reinvested by the holder of such redeemed preferred shares in the Debenture. Net proceeds from the private placement which is approximately $911,000 will be used by InNexus for research and development and general corporate business.

In connection with the private placement, certain insiders of InNexus comprised of the Chairman & CEO, some members of the Board and senior management, participated on the same terms in the offering for an aggregate of approximately 19% of the issued Debenture. InNexus paid a $7,000 finders' fee or 7% of the proceeds was paid to an investment company from the sale of the Debentures to purchasers referred by such finder in accordance with the policies of the TSX Venture Exchange.

Participation in the private placement by insiders of InNexus is considered to be a related-party transaction as defined under Multilateral Instrument 61-101. The transaction is, however, exempt from the formal valuation and minority shareholder approval requirements under the Instrument as neither the fair market value of the securities being issued nor the consideration paid exceeds 25 percent of InNexus' market capitalization.

Upon conversion of the Debenture,
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
2. InNexus Biotechnology Receives Patent Grants in Europe
3. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
4. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
5. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
6. InNexus Biotechnology Strengthens Patent Team With New Leadership
7. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
10. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
11. Mach One Completes Note Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013   Oligomerix, Inc. , ... disease modifying therapeutics for Alzheimer,s disease (AD) and ... its Series B financing, which includes both issuance ... would represent approximately $2.8M in new investments in ... supported the raise. Funding from ...
(Date:5/22/2013)... May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today ... Second Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer of ... on May 30 at 1:30 p.m. Eastern Time.  A live ... on the Investors page of the Cleveland BioLabs website at ...
(Date:5/22/2013)... Envera announced today that Michael McErlean has ... has an extensive background in cell production and served ... , Mike Matheny, President and Owner of ... join our team”. “Mike’s background is perfectly suited to ... and downstream processing equipment”, added Matheny. “Mike’s hands on ...
(Date:5/21/2013)... WEST PALM BEACH, Fla. , May 21, ... Inc. (NYSE: FCN ), the global ... and enhance their enterprise value (the "Company"), announced ... sciences focused personnel that were formerly included within ... Forensic and Litigation Consulting segment to form a ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Envera Appoints Michael McErlean Fermentation Manager 2FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2
... Oct. 27 In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to the ... internet on Wednesday, November 3, 2010 at 4:30 pm ...   http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ...
... Oct. 27 Regenicin, Inc. (OTC Bulletin Board: ... next-generation tissue-engineered skin substitutes to restore the qualities of ... Gervaise Gerstner to the company,s Scientific Advisory Board. Dr. ... of Dermatology at Mount Sinai Hospital in New York. ...
... ROCKVILLE, Md., Oct. 26 MacroGenics, Inc., a ... today that it has entered into a global ... to discover, develop and commercialize Dual-Affinity Re-Targeting (DART™) ... DART technology is a proprietary, bi-specific antibody platform ...
Cached Biology Technology:DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call 2Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board 2MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer 2MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer 3
(Date:5/21/2013)... Australian scientists have charted the path of insulin action ... provides a comprehensive blueprint for understanding what goes wrong ... Sean Humphrey and Professor David James from Sydney,s Garvan ... early online edition of the prestigious journal Cell ... hormone plays a very important role in the body ...
(Date:5/20/2013)... (MAY 20, 2013) University of Minnesota Medical School ... in partnership with the University,s Brain Tumor Program, have ... sheath tumors (MPNST) that allow them to discover new ... , The research was published this week in the ... Beauty transposon method, researchers in the lab of David ...
(Date:5/20/2013)... A National Science Foundation (NSF) planning grant will help ... a joint program of the University of Illinois at ... , "CARD will be devoted to research in drying ... products; forestry and paper products; chemical products; textiles; and ... of food science and human nutrition and the Illinois ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2NSF approves planning grant for Center for Advanced Research in Drying 2
... The FASEB MARC Program is pleased to announce ... recipients of the 2011FASEB Postdoctoral Professional Development and ... Enrichment Award (funded by a grant from the ... of Health) was established to recognize outstanding achievement ...
... their skin cells provides protection from the damage caused by ... that melanin, which is produced by multitudes of the planet,s ... In certain microbes, in particular some organisms from near ... been linked to increased growth in the presence of ...
... (VBI) at Virginia Tech will continue and expand ... Computer as part of a new National Science ... usher in a paradigm shift in the way ... platform and relevant technologies," said Harold "Skip" Garner, ...
Cached Biology News:Recipients of the 2011 Postdoctoral Professional Development and Enrichment Award 2Melanin's 'trick' for maintaining radioprotection studied 2VBI, Convey Computer partner to deliver technology to biomedical, life sciences researchers 2
Anti-NCAPD3 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunoprecipitation, Western Blot...
... BIP-NC H-IPMIK-OH Lyophilized solid. ... LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT GAS. A ... V5 (Cat. No. 196810) that serves as ... apoptosis (~200 μM). Purity: ≥97% by ...
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... flexible, fully automated microplate strip washer for 96- ... automated microplate strip washing capability, the Columbus combines ... operation. , Features ... 8, 12 or 16 channels, crosswise aspiration, overflow ...
Biology Products: